Format

Send to

Choose Destination
Pharmacogenomics. 2000 Aug;1(3):267-80.

The use of proteomics in ophthalmic research.

Author information

1
Alcon Research Ltd, Fort Worth, TX 76134, USA. tom.steely@alconlabs.com

Abstract

The goal of molecular ophthalmology is the early detection and therapeutic treatment of eye disease. Genomic technologies have profoundly enhanced the discovery of ocular disease candidate genes. Proteomics, the protein cognate of genomic technology, offers a means to monitor changes in the expression of a given ocular protein(s) and its post-translational modification, identify novel therapeutic targets and evaluate pharmacological effects on a given metabolic pathway. Using both tissue and cultured cells, numerous laboratories have begun to catalogue changes in ocular protein expression in normal, diseased and ageing subjects. Herein, we review published proteomic literature in the broad context of ophthalmic diseases involving various tissues of the eye.

PMID:
11256578
DOI:
10.1517/14622416.1.3.267
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center